Experienced in WT1-Related Wilms Tumor Syndromes

Dr. Shaachi N. Gupta

Oncology | Hematology | Transfusion Medicine
Florida Cancer Specialists & Research Institute, LLC
Florida Cancer Specialists And Research Institute, LLC
4801 S Congress Ave, Suite 400, 
Lake Worth, FL 
Accepting New Patients
Offers Telehealth

Experienced in WT1-Related Wilms Tumor Syndromes
Florida Cancer Specialists & Research Institute, LLC
Florida Cancer Specialists And Research Institute, LLC
4801 S Congress Ave, Suite 400, 
Lake Worth, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Shaachi Gupta is an Oncologist and a Hematologist in Lake Worth, Florida. Dr. Gupta is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Thymic Epithelial Tumor, and Malignant Mixed Mullerian Tumor. Dr. Gupta is currently accepting new patients.

Her clinical research consists of participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Transfusion Medicine
Licenses
Internal Medicine in FL
Hospital Affiliations
Bethesda Hospital East
Jupiter Medical Center
Good Samaritan Medical Center
Hca Florida Jfk Hospital
Languages Spoken
English
Hindi
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE, LLC
4801 S Congress Ave, Suite 400, Lake Worth, FL 33461
Call: 561-366-4100

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


5 Clinical Trials

Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Enrollment Status: Active_not_recruiting
Publish Date: December 10, 2025
Intervention Type: Drug
Study Drugs: tucatinib, T-DM1
Study Phase: Phase 3
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)
Enrollment Status: Active_not_recruiting
Publish Date: May 23, 2025
Intervention Type: Drug
Study Drugs: ONC-392, Pembrolizumab
Study Phase: Phase 1/Phase 2
postMONARCH: A Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib Plus Fulvestrant to Placebo Plus Fulvestrant in Participants With HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy
postMONARCH: A Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib Plus Fulvestrant to Placebo Plus Fulvestrant in Participants With HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Fulvestrant
Study Phase: Phase 3
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
Enrollment Status: Withdrawn
Publish Date: September 06, 2019
Intervention Type: Drug
Study Phase: Phase 4
View 4 Less Clinical Trials
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Abraham Schwarzberg
Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Abraham Schwarzberg
Hematology | Oncology

Cancer Center Of South Florida PLLC

1630 S Congress Ave, Suite 200, 
Palm Springs, FL 
 (2.2 miles away)
561-253-3980
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Abraham Schwarzberg is a Hematologist and an Oncologist in Palm Springs, Florida. Dr. Schwarzberg is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC).

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Rakesh Singal
Oncology | Hematology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Rakesh Singal
Oncology | Hematology

University Of Miami

1475 Nw 12th Ave, 
Miami, FL 
 (56.9 miles away)
Languages Spoken:
English, Hindi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Rakesh Singal is an Oncologist and a Hematologist in Miami, Florida. Dr. Singal is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Muscle Invasive Bladder Cancer, WT1-Related Wilms Tumor Syndromes, and Chromophobe Renal Cell Carcinoma. Dr. Singal is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Vijay Narendran
Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Vijay Narendran
Hematology | Oncology

Cancer Center Of South Florida PLLC

1630 S Congress Ave, Suite 200, 
Palm Springs, FL 
 (2.2 miles away)
561-253-3980
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Vijay Narendran is a Hematologist and an Oncologist in Palm Springs, Florida. Dr. Narendran is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Thrombocytopenia, Large-Cell Immunoblastic Lymphoma, Anemia, Adult Soft Tissue Sarcoma, and Bone Marrow Aspiration.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gupta's expertise for a condition
ConditionClose
      • Advanced
      • Breast Cancer
        Dr. Gupta is
        Advanced
        . Learn about Breast Cancer.
        See more Breast Cancer experts
      • Experienced
      • Agranulocytosis
        Dr. Gupta is
        Experienced
        . Learn about Agranulocytosis.
        See more Agranulocytosis experts
      • ALK-Positive Non-Small Cell Lung Cancer
        Dr. Gupta is
        Experienced
        . Learn about ALK-Positive Non-Small Cell Lung Cancer.
        See more ALK-Positive Non-Small Cell Lung Cancer experts
      • Anal Cancer
        Dr. Gupta is
        Experienced
        . Learn about Anal Cancer.
        See more Anal Cancer experts
      • Anemia
        Dr. Gupta is
        Experienced
        . Learn about Anemia.
        See more Anemia experts
      • Angiosarcoma
        Dr. Gupta is
        Experienced
        . Learn about Angiosarcoma.
        See more Angiosarcoma experts
      • Bone Tumor
        Dr. Gupta is
        Experienced
        . Learn about Bone Tumor.
        See more Bone Tumor experts
      View All 72 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile
      For Patients
      • Our Story
      • How MediFind Works
      • Conditions A-Z
      • Doctor Directory
      • Symptoms Directory
      • Procedures Directory
      • Treatment Directory
      • Drug Directory
      • Infusion Center Finder
      • FAQ
      • Contact Us
      For Providers and Practices
      • Claim Your Profile
      • Newsroom
      Business Solutions
      • Provider
      • Network Solutions
      Additional Resources
      • Consumer Health Data Privacy Policy
      • Privacy Policy
      • Terms of Use
      • Advertising Policy
      • Content Policy
      Subscribe to our newsletter

      Sign up to stay informed about MediFind and get wellness sent your way.

      Close

        By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

        Bullet PinMediFind
        Follow us on
        This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
        © 2026 All Rights Reserved